Acquiring Company
Supernus Pharmaceuticals
Acquired Company
SAGE Therapeutics
RockvilleCambridgeBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharmaBiotechnologyHealthcareHealth CareTherapeuticsDescription
Supernus Pharmaceuticals, Inc. has completed its acquisition of SAGE Therapeutics, Inc. for USD 8.50 per share on July 31, 2025. This acquisition integrates SAGE's central nervous system drug pipeline into Supernus's expanding neuropsychiatry portfolio. The deal aims to enhance Supernus's commercial platform with new products like Zurzuvae.
Quick answer
Supernus Pharmaceuticals is acquiring SAGE Therapeutics, announced July 31, 2025. Supernus Pharmaceuticals is based in Rockville, Maryland, United States.
- How much did Supernus Pharmaceuticals pay for SAGE Therapeutics?
- The deal value was not disclosed.
- What does Supernus Pharmaceuticals do?
- Supernus Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on developing and commercializing products for the treatment of central nervous system (CNS) diseases.
- Where are Supernus Pharmaceuticals and SAGE Therapeutics based?
- Supernus Pharmaceuticals is based in Rockville, Maryland, United States. SAGE Therapeutics is based in Cambridge, Massachusetts, United States.
- Who are the decision-makers at Supernus Pharmaceuticals?
- Fundz holds 1 contact at Supernus Pharmaceuticals. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Therapeutics and Pharmaceutical
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- AbbVie completes acquisition of Capstan Therapeutics (August 19, 2025)
- AbbVie to acquire Capstan Therapeutics (July 15, 2025)
- AbbVie to acquire Capstan Therapeutics for $2.1B, $2.1B (June 30, 2025)
- AbbVie acquires Gilgamesh Pharmaceuticals' bretisilocin (September 3, 2025)
- AbbVie to acquire Gilgamesh Pharmaceuticals (July 31, 2025)
- BioMarin completes acquisition of Inozyme Pharma (July 1, 2025)
Who to call at Supernus Pharmaceuticals, and when
When Supernus Pharmaceuticals changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Supernus Pharmaceuticals raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Supernus Pharmaceuticals, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Supernus Pharmaceuticals. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Supernus Pharmaceuticals makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired SAGE Therapeutics?
SAGE Therapeutics was acquired by Supernus Pharmaceuticals, based in Rockville. The deal was reported on July 31, 2025. Supernus Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Supernus Pharmaceuticals is privately held and operates in Biotechnology.
When did Supernus Pharmaceuticals acquire SAGE Therapeutics?
Supernus Pharmaceuticals's acquisition of SAGE Therapeutics was reported on July 31, 2025. Supernus Pharmaceuticals, Inc. has completed its acquisition of SAGE Therapeutics, Inc. for USD 8.50 per share on July 31, 2025. This acquisition integrates SAGE's central nervous system drug pipeline into Supernus's expanding neuropsychiatry portfolio. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does SAGE Therapeutics do?
SAGE Therapeutics, Inc. is a biotechnology company dedicated to developing therapies for central nervous system disorders. Its key product, Zurzuvae, targets postpartum depression. The company was previously independently traded on the Nasdaq. It is privately held, operating in Biotechnology, and is based in Cambridge.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.